Reproductive health company Proov has raised a $9.7M Series A led by Hambrecht Ducera Growth Venture to invest in its newly launched “Complete” product. Other participants in the round include SteelSky Ventures, WCC Partners, LightShip Capital, GingerBread Capital, and Portfolia
Proov is known for its PdG test and associated patented protocol, that lets women confirm ovulation quality, which pertains to when ovulation happens and hormone levels remain elevated for long enough to provide the best chance at successful pregnancy. Since the launch of its original PdG test, Proov has added other products to its portfolio including Proov Predict & Confirm that includes 2 types of tests to both find the 2 most fertile days and confirm ovulation quality. With Proov, women can better determine both when their ovulation is occurring and whether ovulation is occurring optimally, with hormone levels high enough to provide the best chance at successful pregnancy. The newly launched “Complete” product is an at-home hormone testing suite for the four most critical hormones testable in urine, providing FSH, LH, E1G (estrogen marker) and PdG results to women at home.
The Proov Insight App provides an easy to follow protocol, leading to quantitative hormone results associated with Proov products. The protocol concludes with an end of cycle report, explaining overall menstrual cycle results including ovulation quality confirmation, along with suggestions for next steps. The Proov Insight App also stores hormone trends over time.
“I started this company in my basement after my own infertility battle and it has become more than I could have imagined. We are so excited to help women get even better information about their cycles to promote better treatment and ultimately better outcomes. With this funding, Proov is now poised to help women across life stages reach their goals faster and ultimately live better by increasing accessibility to key diagnostic and hormone health supporting solutions – both at home and in partnership with physicians.”, said MFB Fertility’s founder and CEO, Amy Beckley.
MFB Fertility’s CTO and Patent Counsel Jeffrey Schell adds: “The patented devices and protocols created by Proov represent a fundamental shift in the information available to women about their hormone wellness, leveraging the power of a smartphone. In combination with our industry leading app, our patented protocols ensure that Proov will continue to offer the most robust and differentiated offering in the at-home female hormone testing space, which we are excited to build on.”
“What initially drew us to Proov was their traction in the market, but what has impressed us more is their vision to bring high quality, science-backed products that could have a game-changing impact on women’s health”, said Betsy Hambrecht, of Hambrect Ducera Growth Ventures. “We look forward to our partnership and to bringing better products and solutions to advance women’s health.”
